Alpha-1 Biologics

Executive Summary

Alpha-1 Biologics is a private, pre-clinical biotechnology company developing orally available drugs that stimulate the locomotion of Helper T cells and pre-T cells to treat cancer and immune deficiencies. Founded in 2018 and based in Los Angeles, USA, the company also explores HDL/LDL regulation for applications in oncology, HIV/AIDS, and cardiovascular disease. Its differentiated approach aims to replenish immune cells and restore immune function, potentially addressing significant unmet medical needs across multiple therapeutic areas. The company's pipeline is entirely pre-clinical, with no disclosed funding or partnerships, reflecting an early stage of development. The company's technology focuses on orally administered therapeutics, which could offer advantages over injectable immunotherapies in terms of patient convenience and compliance. While the scientific rationale is promising, the pre-clinical stage means substantial de-risking is required through animal studies, IND-enabling toxicology, and eventual clinical trials. The lack of public information on specific candidates, funding, or regulatory milestones limits visibility into near-term value drivers. Alpha-1 Biologics remains a high-risk, early-stage investment opportunity that will require significant progress in pre-clinical validation and capital raising to advance toward clinical development.

Upcoming Catalysts (preview)

• TBDCompletion of IND-Enabling Studies25% success
• TBDLead Candidate Selection and Preclinical Proof-of-Concept Data30% success
• TBDSeries A or Early-Stage Partnership Announcement20% success